Fluticasone propionate/salmeterol (Wixela® Inhub®) dry-powder inhaler in asthma and COPD: a profile of its use in the USA
- 47 Downloads
Wixela® Inhub® is the first therapeutically equivalent, substitutable generic version of Advair Diskus® (fluticasone propionate/salmeterol) approved for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in the USA. Wixela Inhub combines the inhaled corticosteroid fluticasone propionate and the long-acting β2-adrenoceptor agonist salmeterol in a single dry-powder inhaler. Each drug has a different mechanism of action, targeting different and complementary aspects of the pathophysiology of asthma and COPD. The in vitro performance of Wixela Inhub is comparable to that of Advair Diskus at all dosage strengths (100/50 μg, 250/50 μg, and 500/50 μg) and all flow rates. Wixela Inhub has pharmacokinetic and pulmonary therapeutic bioequivalence to Advair Diskus, which has well-established efficacy, tolerability, and safety profiles. The Wixela Inhub device is robust and easy to use without instruction. All three dosage strengths of Wixela Inhub will be offered at a wholesale acquisition cost of up to 70% less than Advair Diskus and the authorized generic equivalent.
The manuscript was reviewed by: T. E. Albertson, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA and VA Northern California Health Care System, Mather, CA, USA; E. M. Kerwin, Clinical Research Institute of Southern Oregon, Medford, OR, USA; J. F. M. van Boven, University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Department of Clinical Pharmacy & Pharmacology, Groningen, Netherlands. During the peer review process, Mylan, the marketing-authorization holder of Wixela® Inhub®, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
H. A. Blair is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.
- 2.GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706.Google Scholar
- 3.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019. Bethesda: Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2019.Google Scholar
- 4.Global strategy for asthma management and prevention: updated 2019. Bethesda: Global Initiative for Asthma (GINA); 2019.Google Scholar
- 6.Asthma and Allergy Foundation of America. Cost of asthma on society. 2019. https://www.aafa.org/cost-of-asthma-on-society/. Accessed 29 Oct 2019.
- 12.Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP): US patient brochure. Morgantown (WV): Mylan Pharmaceuticals Inc.; 2019.Google Scholar
- 13.Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder), for oral inhalation use: US prescribing information. Morgantown (WV): Mylan Pharmaceuticals Inc.; 2019.Google Scholar
- 15.Cooper A, Newcomb C, Canham K, et al. Wixela® Inhub® dry powder inhaler: in vitro performance compared with Advair® Diskus® and inhalation profiles in patients with asthma or chronic obstructive pulmonary disease [abstract no. P788 + poster]. In: American Thoracic Society International Conference. 2019.Google Scholar
- 16.Haughie S, Allan R, Wood N, et al. Equivalent systemic exposure to fluticasone propionate/salmeterol following single inhaled doses from Advair Diskus and Wixela Inhub: results of three pharmacokinetic bioequivalence studies. J Aerosol Med Pulm Drug Deliv. 2019. https://doi.org/10.1089/jamp.2019.1537(Epub 2019).CrossRefPubMedGoogle Scholar
- 17.Allan R, Kerwin EM, White MV, et al. Pulmonary therapeutic bioequivalence of Wixela® Inhub® and Advair® Diskus® in adults with asthma [abstract no. P786 plus poster]. In: American Thoracic Society International Conference. 2019.Google Scholar
- 28.Allan R, Newcomb C, Canham K, et al. Usability and robustness of the Wixela® Inhub® dry powder inhaler [abstract no. P787 + poster]. In: American Thoracic Society International Conference. 2019.Google Scholar
- 29.Mylan. Mylan launches Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a list price 70% less than the brand [media release]. 12 Feb 2019. http://newsroom.mylan.com.